Veracyte, Inc. (VCYT) · Insider trading

What Veracyte's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.

Bought, 12 months

0 insiders, 0 trades

Sold, 12 months

$21.03M

11 insiders, 93% under a plan

Net, 12 months

−$21.03M

bought less sold

Latest filing

2026-09-22

filings read to 2026-10-19

Bought and sold at the market, by month

Two years. Purchases above the line, sales below, in dollars.

Bought Sold Largest month: $8.15M

Who traded, two years

Insider	Bought	Sold	Trades	Last trade	Holds after
Stapley MarcDirector, Chief Executive Officer	–	$11.15M	11	2026-06-04	440,494
Chambers RebeccaChief Financial Officer	–	$2.82M	12	2026-09-04	167,200
McGuire AnnieEVP, General Counsel	–	$2.74M	17	2026-09-04	132,260
Eastham KarinDirector	–	$2.58M	12	2026-06-18	15,626
Jones Evan/ FaDirector	–	$2.00M	7	2025-11-25	29,362
Leite JohnGlobal Chief Commercial Off	–	$1.89M	11	2026-09-21	124,329
Wygant JonathanVP, Chief Accounting Officer	–	$1.80M	5	2026-05-22	45,434
Febbo Phillip G.Chief Scientific & Med Officer	–	$1.79M	7	2026-09-04	135,753
Epstein Robert SDirector	–	$1.77M	3	2026-05-20	52,446
Holstein JensDirector	–	$628,335	4	2026-09-14	27,471
Bhanji MunaDirector	–	$202,485	2	2026-09-01	42,718

Open-market purchases and sales

Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.

Date	Insider	Trade	Shares	Price	Value	Holds after	Filing
2026-09-21	Leite JohnGlobal Chief Commercial Off	Saleplan	4,015	40.00	$160,600	124,329	Form 4
2026-09-14	Holstein JensDirector	Saleplan	5,000	40.95	$204,750	27,471	Form 4
2026-09-04	Febbo Phillip G.Chief Scientific & Med Officer	Saleplan	10,405	42.89	$446,270	135,753	Form 4
2026-09-04	Febbo Phillip G.Chief Scientific & Med Officer	Saleplan	2,705	43.66	$118,100	133,048	Form 4
2026-09-04	Chambers RebeccaChief Financial Officer	Saleplan	2,477	42.81	$106,040	167,200	Form 4
2026-09-04	Chambers RebeccaChief Financial Officer	Saleplan	1,175	43.71	$51,359	166,025	Form 4
2026-09-04	McGuire AnnieEVP, General Counsel	Saleplan	2,154	42.79	$92,170	132,260	Form 4
2026-09-04	McGuire AnnieEVP, General Counsel	Saleplan	1,100	43.67	$48,037	131,160	Form 4
2026-09-01	Bhanji MunaDirector	Saleplan	1,864	42.97	$80,096	42,718	Form 4
2026-06-18	Eastham KarinDirector	Saleplan	3,200	52.78	$168,896	15,626	Form 4
2026-06-18	Eastham KarinDirector	Saleplan	529	53.55	$28,328	15,097	Form 4
2026-06-04	Stapley MarcDirector, Chief Executive Officer	Saleplan	138,051	50.12	$6.92M	440,494	Form 4
2026-06-04	Chambers RebeccaChief Financial Officer	Saleplan	1,600	49.28	$78,848	175,241	Form 4
2026-06-04	Chambers RebeccaChief Financial Officer	Saleplan	1,961	50.09	$98,226	173,280	Form 4
2026-06-04	McGuire AnnieEVP, General Counsel	Saleplan	1,400	49.31	$69,034	139,016	Form 4
2026-06-04	McGuire AnnieEVP, General Counsel	Saleplan	1,776	50.12	$89,013	137,240	Form 4
2026-06-04	Leite JohnGlobal Chief Commercial Off	Saleplan	13,975	50.07	$699,728	132,305	Form 4
2026-05-22	Wygant JonathanVP, Chief Accounting Officer	Sale	24,000	45.40	$1.09M	45,434	Form 4
2026-05-20	Epstein Robert SDirector	Saleplan	10,000	44.01	$440,100	52,446	Form 4
2026-05-06	McGuire AnnieSVP, General Counsel	Saleplan	5,102	38.05	$194,131	148,810	Form 4
2026-05-06	McGuire AnnieSVP, General Counsel	Saleplan	5,102	40.00	$204,080	143,708	Form 4
2026-03-04	Stapley MarcDirector, Chief Executive Officer	Saleplan	19,244	35.56	$684,317	383,833	Form 4
2026-03-04	Stapley MarcDirector, Chief Executive Officer	Saleplan	26,279	36.28	$953,402	357,554	Form 4
2026-03-04	Chambers RebeccaChief Financial Officer	Saleplan	4,400	35.55	$156,420	145,137	Form 4
2026-03-04	Chambers RebeccaChief Financial Officer	Saleplan	13,941	36.33	$506,477	131,196	Form 4
2026-03-04	McGuire AnnieSVP, General Counsel	Saleplan	4,994	35.29	$176,238	96,370	Form 4
2026-03-04	McGuire AnnieSVP, General Counsel	Saleplan	1,664	36.34	$60,470	94,706	Form 4
2026-03-04	Leite JohnChief Commercial Officer-CLIA	Saleplan	5,260	35.19	$185,099	107,580	Form 4
2026-03-02	Febbo Phillip G.Chief Scientific & Med Officer	Saleplan	13,425	36.16	$485,448	117,346	Form 4
2025-12-16	McGuire AnnieSVP, General Counsel	Saleplan	10,639	43.13	$458,860	67,860	Form 4
2025-12-16	McGuire AnnieSVP, General Counsel	Saleplan	100	43.68	$4,368	67,760	Form 4
2025-12-05	Eastham KarinDirector	Saleplan	6,392	44.52	$284,572	27,162	Form 4
2025-12-05	Eastham KarinDirector	Saleplan	12,808	45.84	$587,119	14,354	Form 4
2025-12-05	Eastham KarinDirector	Saleplan	800	46.59	$37,272	13,554	Form 4
2025-12-04	Stapley MarcDirector, Chief Executive Officer	Saleplan	4,448	46.90	$208,611	321,823	Form 4
2025-12-04	Stapley MarcDirector, Chief Executive Officer	Saleplan	3,220	47.35	$152,467	318,603	Form 4
2025-12-04	Chambers RebeccaChief Financial Officer	Saleplan	8,537	46.61	$397,910	114,237	Form 4
2025-12-04	Chambers RebeccaChief Financial Officer	Saleplan	4,741	47.25	$224,012	109,496	Form 4
2025-12-04	McGuire AnnieSVP, General Counsel	Saleplan	720	47.10	$33,912	79,201	Form 4
2025-12-04	McGuire AnnieSVP, General Counsel	Saleplan	702	47.51	$33,352	78,499	Form 4

51 more

2025-12-04	Leite JohnChief Commercial Officer-CLIA	Saleplan	1,278	47.51	$60,718	82,113	Form 4
2025-11-25	Jones Evan/ FaDirector	Saleplan	1,106	50.25	$55,576	29,362	Form 4
2025-11-25	Leite JohnChief Commercial Officer-CLIA	Saleplan	2,808	50.00	$140,400	86,291	Form 4
2025-11-20	Holstein JensDirector	Saleplan	1,491	40.95	$61,056	35,708	Form 4
2025-11-20	Holstein JensDirector	Saleplan	7,049	42.48	$299,442	28,659	Form 4
2025-11-20	Holstein JensDirector	Saleplan	1,460	43.21	$63,087	27,199	Form 4
2025-11-10	Wygant JonathanVP, Chief Accounting Officer	Sale	5,102	42.33	$215,968	38,745	Form 4
2025-11-07	Wygant JonathanVP, Chief Accounting Officer	Sale	5,818	40.21	$233,942	43,847	Form 4
2025-11-05	Jones Evan/ FaDirector	Saleplan	408	41.74	$17,030	73,256	Form 4
2025-11-05	Jones Evan/ FaDirector	Saleplan	1,126	43.03	$48,452	72,130	Form 4
2025-11-05	Jones Evan/ FaDirector	Saleplan	10,837	43.80	$474,661	61,293	Form 4
2025-11-05	Jones Evan/ FaDirector	Saleplan	5,872	45.07	$264,651	55,421	Form 4
2025-11-05	Jones Evan/ FaDirector	Saleplan	24,296	45.73	$1.11M	31,125	Form 4
2025-11-05	Jones Evan/ FaDirector	Saleplan	657	46.38	$30,472	30,468	Form 4
2025-11-05	Eastham KarinDirector	Saleplan	9,674	40.02	$387,153	13,554	Form 4
2025-11-05	Chambers RebeccaChief Financial Officer	Saleplan	7,000	41.00	$287,000	126,158	Form 4
2025-11-05	McGuire AnnieSVP, General Counsel	Saleplan	6,466	40.00	$258,640	82,973	Form 4
2025-10-06	Febbo Phillip G.Chief Scientific & Med Officer	Saleplan	8,349	36.02	$300,731	92,441	Form 4
2025-10-01	Epstein Robert SDirector	Saleplan	21,473	35.08	$753,273	62,446	Form 4
2025-10-01	McGuire AnnieSVP, General Counsel	Saleplan	2,160	35.00	$75,600	89,439	Form 4
2025-10-01	Leite JohnChief Commercial Officer-CLIA	Saleplan	2,539	35.00	$88,865	89,099	Form 4
2025-09-19	McGuire AnnieSVP, General Counsel	Saleplan	2,283	33.69	$76,914	91,599	Form 4
2025-09-04	Stapley MarcDirector, Chief Executive Officer	Saleplan	7,667	30.41	$233,153	334,185	Form 4
2025-06-13	Bhanji MunaDirector	Saleplan	4,589	26.67	$122,389	29,989	Form 4
2025-06-13	Eastham KarinDirector	Saleplan	4,590	26.66	$122,369	13,907	Form 4
2025-06-04	Leite JohnChief Commercial Officer-CLIA	Saleplan	2,809	27.20	$76,405	94,540	Form 4
2025-03-07	Leite JohnChief Commercial Officer-CLIA	Saleplan	2,400	31.04	$74,496	105,260	Form 4
2025-03-07	Leite JohnChief Commercial Officer-CLIA	Saleplan	5,011	31.96	$160,152	100,249	Form 4
2025-03-04	McGuire AnnieSVP, General Counsel	Saleplan	1,142	33.69	$38,474	70,308	Form 4
2025-03-04	Stapley MarcDirector, Chief Executive Officer	Saleplan	28,189	32.82	$925,163	292,543	Form 4
2025-03-04	Stapley MarcDirector, Chief Executive Officer	Saleplan	23,414	33.91	$793,969	269,129	Form 4
2025-03-04	Stapley MarcDirector, Chief Executive Officer	Saleplan	1,094	34.37	$37,601	268,035	Form 4
2025-03-04	Febbo Phillip G.Chief Scientific & Med Officer	Saleplan	4,467	32.86	$146,786	86,110	Form 4
2025-03-04	Febbo Phillip G.Chief Scientific & Med Officer	Saleplan	3,570	33.95	$121,202	82,540	Form 4
2025-02-27	Leite JohnChief Commercial Officer-CLIA	Sale	5,746	33.84	$194,445	79,070	Form 4
2025-02-03	Chambers RebeccaChief Financial Officer	Saleplan	527	43.85	$23,109	113,510	Form 4
2025-01-02	Eastham KarinDirector	Saleplan	5,309	40.12	$212,997	23,188	Form 4
2025-01-02	Eastham KarinDirector	Saleplan	4,691	40.50	$189,986	18,497	Form 4
2024-12-13	Stapley MarcDirector, Chief Executive Officer	Saleplan	5,190	43.37	$225,090	307,745	Form 4
2024-12-13	Stapley MarcDirector, Chief Executive Officer	Saleplan	400	44.14	$17,656	307,345	Form 4
2024-12-04	McGuire AnnieSVP, General Counsel	Saleplan	18,699	44.02	$823,130	72,869	Form 4
2024-12-04	Febbo Phillip G.Chief Scientific & Med Officer	Saleplan	3,934	44.09	$173,450	82,414	Form 4
2024-12-03	Wygant JonathanVP, Chief Accounting Officer	Sale	956	43.36	$41,452	40,270	Form 4
2024-12-03	Chambers RebeccaChief Financial Officer	Saleplan	7,000	43.23	$302,610	114,037	Form 4
2024-12-03	Leite JohnChief Commercial Officer-CLIA	Sale	1,050	43.25	$45,412	73,810	Form 4
2024-11-27	Wygant JonathanVP, Chief Accounting Officer	Sale	5,032	42.89	$215,822	42,313	Form 4
2024-11-19	Eastham KarinDirector	Saleplan	1,600	36.77	$58,832	31,628	Form 4
2024-11-19	Eastham KarinDirector	Saleplan	3,006	37.77	$113,537	28,622	Form 4
2024-11-19	Eastham KarinDirector	Saleplan	10,125	38.76	$392,445	18,497	Form 4
2024-11-12	Epstein Robert SDirector	Saleplan	15,000	38.32	$574,800	44,598	Form 4
2024-11-12	Chambers RebeccaChief Financial Officer	Saleplan	15,275	38.34	$585,644	124,501	Form 4

Grants, exercises and other transactions

Pay, tax and paperwork rather than a choice to trade at the market price. Two years.

57 × shares withheld for tax44 × grant or award11 × option exercise

Show them

Date	Insider	What	Shares	Price	Holds after	Filing
2026-09-02	Stapley MarcDirector, Chief Executive Officer	Shares withheld for tax F	−8,782	44.88	432,073	Form 4
2026-09-02	Wygant JonathanVP, Chief Accounting Officer	Shares withheld for tax F	−1,361	44.88	43,226	Form 4
2026-09-02	Febbo Phillip G.Chief Scientific & Med Officer	Shares withheld for tax F	−3,639	44.88	146,158	Form 4
2026-09-02	Chambers RebeccaChief Financial Officer	Shares withheld for tax F	−3,603	44.88	169,677	Form 4
2026-09-02	McGuire AnnieEVP, General Counsel	Shares withheld for tax F	−3,215	44.88	134,414	Form 4
2026-09-02	Leite JohnGlobal Chief Commercial Off	Shares withheld for tax F	−3,961	44.88	128,344	Form 4
2026-06-11	Jones Evan/ FaDirector	Grant or award A	+5,272	–	34,634	Form 4
2026-06-11	Eastham KarinDirector	Grant or award A	+5,272	–	18,826	Form 4
2026-06-11	Epstein Robert SDirector	Grant or award A	+5,272	–	57,718	Form 4
2026-06-11	Shafer David BrentDirector	Grant or award A	+5,272	–	31,100	Form 4
2026-06-11	Holstein JensDirector	Grant or award A	+5,272	–	32,471	Form 4
2026-06-11	Bhanji MunaDirector	Grant or award A	+5,272	–	44,582	Form 4
2026-06-11	Barr EliavDirector	Grant or award A	+5,272	–	56,461	Form 4
2026-06-11	Miller Thomas F.Director	Grant or award A	+5,272	–	31,100	Form 4
2026-06-04	Stapley MarcDirector, Chief Executive Officer	Option exercise M	+138,051	36.60	578,545	Form 4
2026-06-02	Stapley MarcDirector, Chief Executive Officer	Shares withheld for tax F	−9,012	47.80	440,494	Form 4
2026-06-02	Wygant JonathanVP, Chief Accounting Officer	Shares withheld for tax F	−1,361	47.80	44,073	Form 4
2026-06-02	Febbo Phillip G.Chief Scientific & Med Officer	Shares withheld for tax F	−3,730	47.80	149,797	Form 4
2026-06-02	Chambers RebeccaChief Financial Officer	Shares withheld for tax F	−3,693	47.80	176,841	Form 4
2026-06-02	McGuire AnnieEVP, General Counsel	Shares withheld for tax F	−3,292	47.80	140,416	Form 4
2026-06-02	Leite JohnGlobal Chief Commercial Off	Shares withheld for tax F	−4,059	47.80	146,280	Form 4
2026-05-22	Wygant JonathanVP, Chief Accounting Officer	Option exercise M	+24,000	24.80	69,434	Form 4
2026-04-10	Haas Kevin RichardChief Dev and Tech Officer	Grant or award A	+44,221	–	44,221	Form 4
2026-03-06	Stapley MarcDirector, Chief Executive Officer	Grant or award A	+92,099	–	449,653	Form 4
2026-03-06	Wygant JonathanVP, Chief Accounting Officer	Grant or award A	+10,525	–	45,434	Form 4
2026-03-06	Febbo Phillip G.Chief Scientific & Med Officer	Grant or award A	+29,603	–	146,949	Form 4
2026-03-06	Febbo Phillip G.Chief Scientific & Med Officer	Grant or award A	+6,578	–	153,527	Form 4
2026-03-06	Chambers RebeccaChief Financial Officer	Grant or award A	+36,181	–	167,377	Form 4
2026-03-06	Chambers RebeccaChief Financial Officer	Grant or award A	+13,157	–	180,534	Form 4
2026-03-06	McGuire AnnieSVP, General Counsel	Grant or award A	+32,892	–	127,598	Form 4
2026-03-06	McGuire AnnieSVP, General Counsel	Grant or award A	+26,314	–	153,912	Form 4
2026-03-06	Leite JohnChief Commercial Officer-CLIA	Grant or award A	+36,181	–	143,761	Form 4
2026-03-06	Leite JohnChief Commercial Officer-CLIA	Grant or award A	+6,578	–	150,339	Form 4
2026-03-02	Stapley MarcDirector, Chief Executive Officer	Shares withheld for tax F	−19,455	36.01	403,077	Form 4
2026-03-02	Wygant JonathanVP, Chief Accounting Officer	Shares withheld for tax F	−3,006	36.01	34,909	Form 4
2026-03-02	Febbo Phillip G.Chief Scientific & Med Officer	Shares withheld for tax F	−6,035	36.01	130,771	Form 4
2026-03-02	Chambers RebeccaChief Financial Officer	Shares withheld for tax F	−7,234	36.01	149,537	Form 4
2026-03-02	McGuire AnnieSVP, General Counsel	Shares withheld for tax F	−6,902	36.01	101,364	Form 4
2026-03-02	Leite JohnChief Commercial Officer-CLIA	Shares withheld for tax F	−7,517	36.01	112,840	Form 4
2026-02-26	Stapley MarcDirector, Chief Executive Officer	Grant or award A	+139,074	–	458,373	Form 4
2026-02-26	Stapley MarcDirector, Chief Executive Officer	Shares withheld for tax F	−35,841	38.75	422,532	Form 4
2026-02-26	Febbo Phillip G.Chief Scientific & Med Officer	Grant or award A	+71,806	–	161,292	Form 4
2026-02-26	Febbo Phillip G.Chief Scientific & Med Officer	Shares withheld for tax F	−24,486	38.75	136,806	Form 4
2026-02-26	Chambers RebeccaChief Financial Officer	Grant or award A	+59,324	–	168,820	Form 4
2026-02-26	Chambers RebeccaChief Financial Officer	Shares withheld for tax F	−12,049	38.75	156,771	Form 4
2026-02-26	McGuire AnnieSVP, General Counsel	Grant or award A	+50,999	–	119,133	Form 4
2026-02-26	McGuire AnnieSVP, General Counsel	Shares withheld for tax F	−10,867	38.75	108,266	Form 4
2026-02-26	Leite JohnChief Commercial Officer-CLIA	Grant or award A	+47,149	–	129,262	Form 4
2026-02-26	Leite JohnChief Commercial Officer-CLIA	Shares withheld for tax F	−8,905	38.75	120,357	Form 4
2025-12-05	Eastham KarinDirector	Option exercise M	+10,000	7.94	23,554	Form 4
2025-12-05	Eastham KarinDirector	Option exercise M	+10,000	7.60	33,554	Form 4
2025-12-02	Stapley MarcDirector, Chief Executive Officer	Shares withheld for tax F	−7,914	46.16	326,271	Form 4
2025-12-02	Wygant JonathanVP, Chief Accounting Officer	Shares withheld for tax F	−1,325	46.16	37,420	Form 4
2025-12-02	Febbo Phillip G.Chief Scientific & Med Officer	Shares withheld for tax F	−2,955	46.16	89,486	Form 4
2025-12-02	Chambers RebeccaChief Financial Officer	Shares withheld for tax F	−3,384	46.16	122,774	Form 4
2025-12-02	McGuire AnnieSVP, General Counsel	Shares withheld for tax F	−3,052	46.16	79,921	Form 4
2025-12-02	Leite JohnChief Commercial Officer-CLIA	Shares withheld for tax F	−2,900	46.16	83,391	Form 4
2025-11-05	Jones Evan/ FaDirector	Option exercise M	+10,000	5.28	53,664	Form 4
2025-11-05	Jones Evan/ FaDirector	Option exercise M	+10,000	7.94	63,664	Form 4
2025-11-05	Jones Evan/ FaDirector	Option exercise M	+10,000	7.60	73,664	Form 4
2025-10-28	Wygant JonathanVP, Chief Accounting Officer	Grant or award A	+2,886	–	49,665	Form 4
2025-10-01	Epstein Robert SDirector	Option exercise M	+10,000	7.94	83,919	Form 4
2025-09-02	Wygant JonathanVP, Chief Accounting Officer	Shares withheld for tax F	−1,648	30.11	46,779	Form 4
2025-09-02	Leite JohnChief Commercial Officer-CLIA	Shares withheld for tax F	−2,902	30.11	91,638	Form 4
2025-09-02	Febbo Phillip G.Chief Scientific & Med Officer	Shares withheld for tax F	−2,955	30.11	100,790	Form 4
2025-09-02	Stapley MarcDirector, Chief Executive Officer	Shares withheld for tax F	−7,914	30.11	341,852	Form 4
2025-09-02	McGuire AnnieSVP, General Counsel	Shares withheld for tax F	−3,507	30.11	93,882	Form 4
2025-09-02	Chambers RebeccaChief Financial Officer	Shares withheld for tax F	−5,371	30.11	133,158	Form 4
2025-06-18	Shafer David BrentDirector	Grant or award A	+9,321	–	25,828	Form 4
2025-06-18	Miller Thomas F.Director	Grant or award A	+9,321	–	25,828	Form 4
2025-06-18	Bhanji MunaDirector	Grant or award A	+9,321	–	39,310	Form 4
2025-06-18	Barr EliavDirector	Grant or award A	+9,321	–	51,189	Form 4
2025-06-18	Epstein Robert SDirector	Grant or award A	+9,321	–	73,919	Form 4
2025-06-18	Jones Evan/ FaDirector	Grant or award A	+9,321	–	43,664	Form 4
2025-06-18	Holstein JensDirector	Grant or award A	+9,321	–	37,199	Form 4
2025-06-18	Eastham KarinDirector	Grant or award A	+9,321	–	23,228	Form 4
2025-06-02	Stapley MarcDirector, Chief Executive Officer	Shares withheld for tax F	−9,399	26.74	349,237	Form 4
2025-06-02	Febbo Phillip G.Chief Scientific & Med Officer	Shares withheld for tax F	−2,955	26.74	103,745	Form 4
2025-06-02	Wygant JonathanVP, Chief Accounting Officer	Shares withheld for tax F	−1,848	26.74	47,915	Form 4
2025-06-02	Leite JohnChief Commercial Officer-CLIA	Shares withheld for tax F	−2,900	26.74	97,349	Form 4
2025-06-02	Chambers RebeccaChief Financial Officer	Shares withheld for tax F	−5,370	26.74	138,529	Form 4
2025-06-02	McGuire AnnieSVP, General Counsel	Shares withheld for tax F	−3,505	26.74	97,003	Form 4
2025-03-06	Stapley MarcDirector, Chief Executive Officer	Grant or award A	+90,601	–	358,636	Form 4
2025-03-06	McGuire AnnieSVP, General Counsel	Grant or award A	+30,200	–	100,508	Form 4
2025-03-06	Leite JohnChief Commercial Officer-CLIA	Grant or award A	+36,240	–	107,660	Form 4
2025-03-06	Chambers RebeccaChief Financial Officer	Grant or award A	+30,200	–	143,899	Form 4
2025-03-06	Febbo Phillip G.Chief Scientific & Med Officer	Grant or award A	+24,160	–	106,700	Form 4
2025-03-06	Wygant JonathanVP, Chief Accounting Officer	Grant or award A	+13,288	–	49,763	Form 4
2025-03-02	McGuire AnnieSVP, General Counsel	Shares withheld for tax F	−8,255	34.76	71,450	Form 4
2025-03-02	Chambers RebeccaChief Financial Officer	Shares withheld for tax F	−11,070	34.76	113,699	Form 4
2025-03-02	Wygant JonathanVP, Chief Accounting Officer	Shares withheld for tax F	−4,301	34.76	36,475	Form 4
2025-03-02	Febbo Phillip G.Chief Scientific & Med Officer	Shares withheld for tax F	−6,754	34.76	90,577	Form 4
2025-03-02	Stapley MarcDirector, Chief Executive Officer	Shares withheld for tax F	−20,324	34.76	320,732	Form 4
2025-03-02	Leite JohnChief Commercial Officer-CLIA	Shares withheld for tax F	−7,650	34.76	71,420	Form 4
2025-02-27	McGuire AnnieSVP, General Counsel	Grant or award A	+13,466	–	86,705	Form 4
2025-02-27	McGuire AnnieSVP, General Counsel	Shares withheld for tax F	−7,000	33.84	79,705	Form 4
2025-02-27	Chambers RebeccaChief Financial Officer	Grant or award A	+23,170	–	136,680	Form 4
2025-02-27	Chambers RebeccaChief Financial Officer	Shares withheld for tax F	−11,911	33.84	124,769	Form 4
2025-02-27	Febbo Phillip G.Chief Scientific & Med Officer	Grant or award A	+30,589	–	113,003	Form 4
2025-02-27	Febbo Phillip G.Chief Scientific & Med Officer	Shares withheld for tax F	−15,672	33.84	97,331	Form 4
2025-02-27	Stapley MarcDirector, Chief Executive Officer	Grant or award A	+67,277	–	375,329	Form 4
2025-02-27	Stapley MarcDirector, Chief Executive Officer	Shares withheld for tax F	−34,273	33.84	341,056	Form 4
2025-02-27	Leite JohnChief Commercial Officer-CLIA	Grant or award A	+11,006	–	84,816	Form 4
2025-01-06	Epstein Robert SDirector	Option exercise M	+20,000	8.04	64,598	Form 4
2025-01-02	Eastham KarinDirector	Option exercise M	+10,000	5.28	28,497	Form 4
2024-12-02	Stapley MarcDirector, Chief Executive Officer	Shares withheld for tax F	−5,748	44.12	312,935	Form 4
2024-12-02	Wygant JonathanVP, Chief Accounting Officer	Shares withheld for tax F	−1,087	44.12	41,226	Form 4
2024-12-02	Febbo Phillip G.Chief Scientific & Med Officer	Shares withheld for tax F	−6,738	44.12	86,348	Form 4
2024-12-02	Chambers RebeccaChief Financial Officer	Shares withheld for tax F	−3,464	44.12	121,037	Form 4
2024-12-02	Leite JohnChief Commercial Officer-CLIA	Shares withheld for tax F	−1,314	44.12	74,860	Form 4
2024-12-02	McGuire AnnieSVP, General Counsel	Shares withheld for tax F	−1,918	44.12	91,568	Form 4
2024-11-12	Epstein Robert SDirector	Option exercise M	+15,000	8.04	59,598	Form 4

How to read it

Buy, sale: Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
Plan: A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
Holds after: The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
Value: Shares times the price the form reports, which is often an average over several fills on the day.

Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.

Veracyte's scores and multiples ›